文献速递肿瘤 PET/CT

[68Ga]Ga-FAPI-04 PET/CT对局部晚期可切除口腔鳞状细胞癌新辅助化疗免疫治疗病理反应的预测价值

Predictive value of [68Ga]Ga-FAPI-04 PET/CT on pathologic response to neoadjuvant chemoimmunotherapy for locally advanced resectable oral squamous cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-23

这项前瞻性研究纳入31例拟接受两周期新辅助化疗免疫治疗(NACI)后行根治性手术的初治口腔鳞状细胞癌(OSCC)患者(III-IVA期),基线及第二周期NACI后行[68Ga]Ga-FAPI-04 PET/CT。最终分析20例,其中8例(40.0%)达到主要病理反应(MPR,含6例病理完全缓解),12例(60.0%)为非MPR。MPR组术前SUVmax为9.38±2.60,显著低于非MPR组的16.20±5.23(P=0.003);MPR组∆SUVmax(%)为-59.10%±13.33,显著低于非MPR组的-15.96%([-52.56%, 66.33%];P=0.002)。作者结论认为[68Ga]Ga-FAPI-04 PET/CT参数能较好预测NACI后MPR,∆SUVs为MPR的显著预测因素,并指出这些发现需在更大队列中验证。

要点

  • MPR组术前SUVmax为9.38±2.60,显著低于非MPR组的16.20±5.23(P=0.003)。
  • MPR组∆SUVmax(%)为-59.10%±13.33,显著低于非MPR组的-15.96%([-52.56%, 66.33%];P=0.002)。
  • 基线SUVmax两组差异无统计学显著(P=0.053);∆SUVs被识别为MPR的显著预测因素,但需在更大队列中验证。

核心结论

  • [68Ga]Ga-FAPI-04 PET/CT参数能较好预测局部晚期可切除口腔鳞状细胞癌患者接受新辅助化疗免疫治疗后达到主要病理反应(MPR)。
  • ∆SUVs被识别为MPR的显著预测因素。
  • 作者指出这些发现需在更大队列中验证。

研究设计与样本

  • 前瞻性研究,纳入31例初治口腔鳞状细胞癌患者(III-IVA期),计划接受两周期新辅助化疗免疫治疗(NACI)后行根治性手术。
  • 基线及第二周期NACI后行[68Ga]Ga-FAPI-04 PET/CT,记录或计算原发肿瘤的半定量PET参数SUVmax、SUVmean、SUVpeak及其变化率(∆SUVs,%)。
  • 最终分析纳入20例患者。

主要发现

  • 8例(40.0%)达到主要病理反应(MPR),其中6例为病理完全缓解(pCR);12例(60.0%)根据术后组织病理学归为非MPR。
  • MPR组术前SUVmax为9.38±2.60,非MPR组为16.20±5.23,MPR组显著低于非MPR组(P=0.003);基线SUVmax两组差异无统计学显著(P=0.053)。
  • MPR组∆SUVmax(%)为-59.10%±13.33,非MPR组为-15.96%([-52.56%, 66.33%]),MPR组显著低于非MPR组(P=0.002)。
  • 术前SUVs及∆SUVs与病理反应显著相关。
  • FAP表达与术前SUVs呈正相关;MPR组CD8及GZMB表达高于非MPR组。

关键数值与推荐

  • MPR定义依据术后组织病理学 findings,包括pCR;原文报告MPR 8例(40.0%),其中pCR 6例;非MPR 12例(60.0%)。
  • 术前SUVmax:MPR组9.38±2.60 vs 非MPR组16.20±5.23(P=0.003)。
  • ∆SUVmax(%):MPR组-59.10%±13.33 vs 非MPR组-15.96%([-52.56%, 66.33%];P=0.002)。
  • 基线SUVmax两组比较P=0.053。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出这些发现需在更大队列中验证(warrant validation in larger cohorts)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study aimed to investigate the performance of [68Ga]Ga-FAPI-04 PET/CT for prediction of pathologic response to neoadjuvant chemoimmunotherapy (NACI) in patients with resectable locally advanced oral squamous cell carcinoma (LAOSCC). METHODS: Thirty-one treatment-naïve OSCC patients (stage III-IVA) scheduled to receive two cycles of NACI followed by radical surgery were enrolled. [68Ga]Ga-FAPI-04 PET/CT was performed at baseline and after the second cycle of NACI. Semiquantitative PET parameters of the primary tumor were recorded or calculated, namely SUVmax, SUVmean, SUVpeak, and their change rates (∆SUVs, %). PET parameters were compared between the two groups, and their correlation with pathologic response, PD-L1, fibroblast activation protein (FAP), granzyme B (GZMB) expression, and infiltration of CD8+ T lymphocytes in the tumor tissues was also analyzed. RESULTS: Twenty patients were included in the final analysis. Eight patients (40.0%) achieved major pathological response (MPR), including 6 with pathologic complete response (pCR), while 12 patients (60.0%) were categorized as non-MPR according to postoperative histopathological findings. The average preoperative SUVmax was significantly lower in the MPR group (9.38 ± 2.60) compared with that in the non-MPR group (16.20 ± 5.23; P = 0.003), while baseline SUVmax was not significantly different (P = 0.053). The ∆SUVmax (%) in the MPR group (- 59.10% ± 13.33) was notably lower than that in the non-MPR group (- 15.96%, [- 52.56%, 66.33%]; P = 0.002). Preoperative SUVs and ∆SUVs were significantly associated with pathologic response. FAP expression was positively correlated with preoperative SUVs, and the MPR group showed higher CD8 and GZMB expression versus the non-MPR group. CONCLUSION: [68Ga]Ga-FAPI-04 PET/CT parameters are able to well predict the achievement of MPR following NACI in patients with LAOSCC. ΔSUVs are identified as significant predictors of MPR. These findings warrant validation in larger cohorts. CLINICAL TRIAL REGISTRATION: This prospective study was reviewed and approved by the Medical Ethics Committee of Zhongnan Hospital, Wuhan University, and was registered online at NIH ClinicalTrials.gov (NCT05034146 & NCT05030597).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jiang Y, Yu Z, Sun Y, et al. Predictive value of [68Ga]Ga-FAPI-04 PET/CT on pathologic response to neoadjuvant chemoimmunotherapy for locally advanced resectable oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2025. PMID: 40548990. doi:10.1007/s00259-025-07414-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。